FDA Puts Cancer Drug Approval on Hold
The FDA delayed a decision on Exelixis' new medicine for colon cancer, leaving patients and doctors waiting for answers.
A new medicine from Exelixis aimed at treating advanced colon cancer faces a delay. The Food and Drug Administration, or FDA, has pushed back its decision. This medicine is a special kind of drug called a kinase inhibitor. It works with another drug, Roche's Tecentriq, to fight cancer that has spread.
This delay means the FDA needs more time to look at the drug's information. They want to make sure it is safe and works well. The FDA must review all details carefully before giving its approval. Patients with metastatic colorectal cancer need new treatments, so this wait is important.
Money Morning Live will watch this situation closely. We will tell you when the FDA makes its final decision. This could affect many patients and the biotech industry.
Source: FierceBiotech
More from Biotech
